Zacks: Brokerages Expect Aileron Therapeutics (ALRN) to Post -$0.52 EPS

Brokerages expect Aileron Therapeutics (NASDAQ:ALRN) to report earnings per share (EPS) of ($0.51) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.49). Aileron Therapeutics reported earnings per share of ($0.45) in the same quarter last year, which indicates a negative year-over-year growth rate of 13.3%. The business is scheduled to report its next quarterly earnings results on Thursday, August 9th.

On average, analysts expect that Aileron Therapeutics will report full-year earnings of ($2.06) per share for the current financial year, with EPS estimates ranging from ($2.24) to ($1.95). For the next fiscal year, analysts expect that the company will report earnings of ($2.20) per share, with EPS estimates ranging from ($2.26) to ($2.11). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.02).

Separately, ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aileron Therapeutics has a consensus rating of “Buy” and a consensus price target of $19.33.

In other news, major shareholder Apple Tree Partners Ii Lp sold 107,904 shares of the stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $6.31, for a total value of $680,874.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Several hedge funds have recently made changes to their positions in ALRN. Bank of New York Mellon Corp acquired a new position in shares of Aileron Therapeutics in the 3rd quarter valued at $135,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth about $165,000. California State Teachers Retirement System bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth about $110,000. Finally, Endurant Capital Management LP grew its holdings in shares of Aileron Therapeutics by 24.0% in the 4th quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares during the last quarter. Institutional investors own 7.94% of the company’s stock.

Aileron Therapeutics opened at $5.45 on Friday, Marketbeat reports. Aileron Therapeutics has a one year low of $5.40 and a one year high of $5.61. The firm has a market cap of $80.32 million and a P/E ratio of -3.08.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply